Pharmaceuticals, Biotechnology and Life Sciences
Bristol-Myers Squibb (BMS) and GeneCentric Diagnostics have teamed up to explore the possibility of GeneCentric’s Cancer Subtype Platform (CSP) could identify translational biomakers for Opdivo, that could help for future clinical trials.
Bristol-Myers Squibb and PsiOxus Therapeutics have entered into an agreement granting Bristol-Myers Squibb exclusive worldwide rights to NG-348, a pre-clinical…
Bristol-Myers Squibb Company has declared an increase of 2.6% percent in the its quarterly dividend, beginning in the first quarter…
Bristol-Myers gets exclusive worldwide rights to develop Nitto’s investigational anti-fibrosis drug
ristol-Myers Squibb Company and Infinity Pharmaceuticals have announced a clinical trial collaboration to evaluate Bristol-Myers Squibb’s Opdivo …
Bristol-Myers Squibb Company and Innate Pharma SA today announced safety data for two Phase I studies conducted by Bristol-Myers Squibb, testing lirilumab in combination with nivolumab or ipilimumab, respectively, in patients with advanced refractory solid tumors.
Bristol-Myers Squibb disappointed investors on Sunday as researchers detailed data for its Opdivo cancer immunotherapy, which was already known to have failed to do better than older chemotherapies in a closely watched clinical trial.
Indian pharmaceutical company Natco Pharma Limited has signed a nonexclusive, royalty free licensing agreement with the Medicines Patent Pool and…
Bristol-Myers Squibb’s closely watched new drug Opdivo, one of the first of a new wave of cancer medicines that boost the immune system, has been rejected as too expensive for treating lung cancer by Britain’s cost watchdog.
Bristol-Myers Squibb has entered into a collaboration agreement with UCLA as part of Bristol-Myers Squibb’s Immuno-Oncology Rare Population Malignancy (I-O RPM) research program in the U.S.